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Abstract:  Arsenic  trioxide,  the  trade  name  Trisenox,  is  a  drug  used  to  treat  acute 
promyleocytic  leukemia  (APL).  Studies  have  demonstrated  that  arsenic  trioxide  slows 
cancer cells growth. Although arsenic influences numerous signal-transduction pathways, 
cell-cycle progression, and/or apoptosis, its apoptotic mechanisms are complex and not 
entirely delineated. The primary objective of this research was to evaluate the effects of 
arsenic trioxide on DNA synthesis and to determine whether arsenic-induced apoptosis is 
mediated via caspase activation, p38 mitogen–activated protein kinase (MAPK), and cell 
cycle  arrest.  To  achieve  this  goal,  lung  cancer  cells  (A549)  were  exposed  to  various 
concentrations (0, 2, 4, 6, 8, and 10 µg/mL) of arsenic trioxide for 48 h. The effect of 
arsenic  trioxide on DNA synthesis  was  determined by  the [
3H]thymidine incorporation 
assay. Apoptosis was determined by the caspase-3 fluorescein isothiocyanate (FITC) assay, 
p38 MAP kinase activity was determined by an immunoblot assay, and cell-cycle analysis 
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was  evaluated  by  the  propidium  iodide  assay.  The  [
3H]thymidine-incorporation  assay 
revealed a dose-related cytotoxic response at high levels of exposure. Furthermore, arsenic 
trioxide modulated caspase 3 activity and induced p38 MAP kinase activation in A549 
cells. However, cell-cycle studies showed no statistically significant differences in DNA 
content at subG1 check point between control and arsenic trioxide treated cells. 
Keywords:  arsenic trioxide (As2O3); [
3H]thymidine incorporation; apoptosis; cell cycle 
regulation; p38 MAP kinase; caspase-3 fluorescein isothiocyanate (FITC) 
 
1. Introduction  
 
Arsenic  compounds  have  been  use  in  Chinese  and  Western  medicine  for  many  years.  Arsenic 
compounds have been used to treat a variety of ailments such as syphilis, yaws, amoebic dysentery and 
trypanosomiasis  [1].  Despite  all  of  the  adverse  health  effects  associated  with  inorganic  arsenic 
exposure, there is some evidence that small amounts of arsenic in the normal diet (10–50 ppb) may be 
beneficial  to  health  [1].  Arsenic  trioxide has  been used as  a mitochondria-targeting drug in acute 
promyelocytic leukemia [2-5]. Arsenic trioxide and arsenic containing compounds are cytotoxic [4-6] 
and capable of triggering apoptosis [6-10]. Their cytotoxic potential has been linked to a decreased 
mitochondrial  potential,  fragmented  DNA,  and  finally  apoptotic  cell  death  [1,6,8,11].  Cellular 
proliferation  or  DNA  synthesis  is  controlled  by  the  cell  cycle.  Biological,  pathophysiological  and 
environmental  factors  can  affect  the  cell  cycle  progression.  It  implies  that  cell  numbers  can  be 
regulated by factors that influence cell survival as well as those that control proliferation, apoptosis  
and differentiation [12]. 
Apoptosis  is  an  active  and  gene  directed  programmed  cell  death.  Its  role  is  to  maintain  tissue 
homeostasis  and  to  eliminate  excess  or  dysfunctional  cells.  Apoptosis  is  characterized  by  several 
morphological changes which include cell shrinkage, membrane blebbing, chromatin condensation, 
and  nuclear  fragmentation  [13].  It  is  also  characterized  by  biochemical  features  such  as  caspase 
cascade, and cleavage of various caspase substrates (caspase 3 and 9 activation) [13,14]. In apoptosis, 
the  functional  integrity  of  the  plasma  membrane  is  long  maintained.  In  addition,  apoptosis  is 
accompanied by internucleosomal DNA fragmentation giving rise to the classical ―ladder‖ pattern on  
DNA electrophoresis [4,12,15].  
Arsenic, in particular, arsenic trioxide can also exert its effect through the activation of the mitogen-
activated protein kinase (MAPK) cascade [16]. Environmental stress signals (ultraviolet light, heat or 
synthesis  inhibitors)  have  been  shown  to  activate  the  c-jun  NH2-  terminal  kinase  (JNK)  and p38 
MAPK pathways, which resulted in stress responses, growth arrest and/or apoptosis [16]. Verma et al. 
were the first to provide evidence that arsenic trioxide activated α and β isoforms of p38 MAP kinase 
in acute promyelocytic leukemia (NB-4) and in an all-trans-retinoic acid resistant NB-4 variant [17]. 
The aims of this study were to evaluate the effects of arsenic trioxide on DNA synthesis and to 
determine  whether  arsenic–induced  apoptosis  is  mediated  via  caspase  activation,  p38  mitogen-
activated protein kinase (MAPK), and cell cycle arrest. Int. J. Environ. Res. Public Health 2010, 7                 
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2. Materials and Methods  
Cell Lines and Chemicals 
 
Human lung carcinoma cell line (A549) and F-12 K medium were purchased from American Type 
Culture  Collection  (ATCC)  (Manassa,  VA).  Fetal  bovine  serum  (FBS),  penicillin/streptomycin/ 
fungizone,  phosphate  buffered  saline  (PBS)  and  trypsin  versene  were  purchased  from  Invitrogen 
(Grand Island, NY). [
3H methyl]Thymidine was obtained from MP Biomedicals (Irvine, CA). Arsenic 
trioxide (As2O3; lot # 02765-24) was purchased from Fisher Scientific (Houston, TX). Caspase-3 FITC 
kit was obtained from EMB Biosciences (San, Diego, CA) and the p38 MAP Kinase assay kit (non-
radioactive) from Cell Signaling Technology, Inc (Danvers, MA). 
 
Cell Culture 
 
A549  cells  were  maintained in  F-12K complete growth medium  (10% FBS, and 1% penicillin 
(10,000 units/mL) and streptomycin (10,000 units/mL) as adherent cells. The cells were grown in a 
humidified  incubator  under  an  atmosphere  of  95%  air  and  5%  CO2  at  37  º C  to  sub-confluence  
(80–95%). After growing to 80–95% confluence, the medium was aspirated off and the cell monolayer 
was washed three times with sterile phosphate buffered saline (PBS). The cell monolayer was treated 
with  1  mL  trypsin  versene  per  plate  and  incubated  briefly  at  37  º C.  The  cells  were  then  viewed 
microscopically to ensure a complete cell detachment. Cells were re-suspended in F-12K complete 
medium and seeded in 13 ×  100 mm tissue culture plates at a density of 5 ×  10
5 cells/plate, prior to 
arsenic trioxide treatment. 
 
[
3H]Thymidine Incorporation Assay 
  
Cells were seeded in 6 well culture plates at a density of 3 ×  10
5 cells/well and the cells grew to 
60%–70% confluent in 3 days. Sub-confluent cells were incubated in serum starved medium (1% fetal 
bovine serum and 1% penicillin (10,000 units/mL)/ streptomycin (10,000 units/mL) overnight, and 
then treated with different doses (0, 2, 4, 6, 8, 10 µg/mL) of arsenic trioxide. Cells were incubated for 
18 h before 1µ Ci/mL [
3H methyl]thymidine was added to each well for an additional 6 h period. The 
incubation of tritiated thymidine was terminated by aspirating the culture medium off, washed 3 times 
with cold phosphate buffered saline pH 7.4 followed by the addition of 2 ml/well of ice-cold 10% 
trichloroacetic acid (TCA) for 20 min at 4 º C. The TCA was aspirated off the cells and the cells were 
washed three times with ice-cold water. After the washing, the cells were solubilized with 1 mL of  
0.5  M  NaOH/well  at  37  º C  for  30  min.  The  [
3H]thymidine  incorporation  was  quantitated  in  a 
scintillation counter (Beckman Instruments). Each treatment group was assayed in triplicates and each 
experiment was repeated at least three times. 
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Caspase-3 FITC Assay 
Cells were seeded in 6 well tissue culture plates at a density of 3 ×  10
5 cells/well and grown to  
60%–70% confluence for 3 days. Sub-confluent cells were placed in serum starved medium (1% fetal 
bovine serum and 1% penicillin (10,000 units/mL)/streptomycin (10,000 units/mL) overnight, and then 
treated with arsenic trioxide at 0, 2, 4, 6 µg/mL, respectively for 48 h. The caspase 3-FITC assay was 
performed using the manufacture’s recommended protocol. Caspase-3 activity was measured using a 
fluorescence-activated cell-sorting (FACS Vantage) system (Becton-Dickinson, San Jose, CA).  
Cell Cycle Analysis  
 Cell cycle analysis was performed as described by Ndebele et al. [18-20]. Briefly, A549 cells were 
seeded on 13 ×  100 mm plates at a density of 3 ×  10
5/ plate
 until 75% confluent. Cells were incubated 
overnight in complete growth medium supplemented with 1% fetal bovine serum. Cells were treated 
with arsenic trioxide at 0, 2, 4, and 6µg/mL for 48 h. After the 48 h incubation, the cells were washed 
with cold PBS, harvested and counted. The cells density of 1 ×  10
6 was spun down at 3000 rpm for  
5 min. The pellet was resuspended in 250 μL of propidium iodide solution. The reaction was incubated 
at  4  º C in  the dark for  1 h.  The cell cycle distribution was  measured using  FACS Vantage flow 
cytometry system. This method allows for the calculation of the percentages of cells in the G0/G1 
(resting phase), S (DNA synthesis) and G2M and apoptotic fractions (sub G1). 
P38 MAP Kinase Assay  
549 cells were treated with arsenic trioxide at 0, 2, 4, and 6 µg/mL for 48 h and subsequently lysed 
and  immunoprecipitated  with  immobilized  phosphor-p38  MAPK  (Thr  180/Tyr  182)  mAb  primary 
antibody. The slurry was incubated with gentle rocking overnight at 4 º C. The immunoprecipitates 
were then washed two times in cell lysis buffer [20 mM Tris (pH 7.5), 150 mM NaCl, 1 mM EDTA, 1 
mM EGTA, 1% Triton, 2.5 mM NaVO4, 1 µg/mL leupeptin] followed by two washes with kinase 
buffer  [25  mM  Tris  (pH7.4),  5  mM  β-glycerolphosphate,  2  mM  DTT,  0.1  mM  NaVO4,  10  mM 
MgCl2]. The immunoprecipitates were resuspended in 50 µL of kinase assay buffer with 200 µM ATP 
and  kinase  substrate  (ATF-2  fusion  protein).  The reaction was  incubated for 30 min at  30º C and 
terminated with 50 µL of 3X sodium dodecylsulfate (SDS) sample buffer. Protein was analyzed by 
SDS-PAGE  and  ATF-2  as  a  substrate  was  assayed  by  western  blotting  and  chemiluminescence 
detection.  
Statistical Analysis 
Date collected from [
3H]thymidine, caspase-3 and cell cycle distribution assays were represented as 
means ±  SEs of three experiments performed in triplicates. They were analyzed by ANOVA using 
Microscoft Windows Excel statistical program, followed by the Student t- test to assess if there were 
any significant differences in mean values between control and each of the ATO treated cells. The 
statistical significance was considered at p < 0.05. 
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3. Results 
 
[
3H]Thymidine Incorporation Assay 
 
[
3H]Thymidine incorporation assay was used to assess DNA synthesis in A549 cells. Data obtained 
from this assay showed a dose dependent effect of arsenic trioxide exposure (Figure 1). DNA synthesis 
decreased as arsenic trioxide concentration increased. The percentages of DNA synthesis were 100 ±  5, 
88  ±   5,  64  ±   3,  13  ±   3,  0.02  ±   0.03,  and  0.02  ±   0.02  for  0,  2,  4,  6,  8,  and  10  µg/mL  arsenic  
trioxide, respectively. 
Figure 1. [
3H]thymidine incorporation assay of A549 cells after 48 h exposure to arsenic 
trioxide.  The  data  is  represented  as  mean  ±   SEM  of  three  experiments  performed  in 
triplicates. The differences were considered statistically significant with a p value < 0.05. 
The significance of the value is indicated by asterisks (*). 
 
 
Caspase 3-FITC Analysis 
 
Data from Figure 2 indicates that caspase-3 levels were 0.074 ±  0.019, 0.19 ±  0.0, 0.46 ±  0.014,  
1.02 ±  0.25 for 0, 2, 4, and 6 µg/mL, respectively. Statistically significant differences (p < 0.05) in 
caspase-3 activity were observed at 4 and 6 µ g/mL arsenic trioxide compared to the control. 
Figure 2. Effect of arsenic trioxide on caspase-3 activity in A549 cells. 
 Int. J. Environ. Res. Public Health 2010, 7                 
 
 
2001 
Effect of Arsenic Trioxide on p38 MAPK Activity 
 
The p38 MAPK activity was measured in the immunoprecipitate with phosphor p38 MAPK mab 
primary antibody in the presence of ATP and GST-ATF-2 fusion protein as substrate. Results showed a 
high expression of p38 MAPK (ATF-2) at 4 µg/mL of arsenic trioxide when compared to the control  
(0 µg/mL) (Figure 3).  
Figure 3a. Effect of arsenic trioxide on p38 MAPK expression in A549 cells.  
 
Figure  3b.  Densiometric  analysis  of  p38  MAPK  expression  in  A549  cells  exposed to 
arsenic trioxide. Data represent the mean values of three individual experiments done in 
triplicates. The intensities of the bands represented in Figure 3a were quantified and plotted 
as relative abundances. 
 
 
Effect of Arsenic Trioxide on Cell Cycle Distribution 
 
The histograms  in  Figure 4  show  the cell cycle distribution of A549 cells treated with arsenic 
trioxide at 0 μg/mL, 2 μg/mL, 4 μg/mL and 6 μg/mL for 48 h. The apoptotic fraction, the sub-G1 phase 
of the cell cycle, is represented by the M1 peak on the histograms. The other phases of the cell cycle  
(S, G1 and G2) are represented on the histograms as M2, M3 and M4, respectively.  
* 
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Figure 4. Representative cell cycle histograms of A549 cells treated with arsenic trioxide 
(0, 2, 4, and 6 µg/mL) for 48 h.  
 
 
The percentages of cells undergoing apoptosis represented by subG1 (M1) were 2.4%, 6.3%, 2.2% 
and 0.97% for 2, 4, and 6 µg/mL for 0, 2, 4, and 6 μg/mL, respectively. 
DNA flow cytometric analysis indicated that treatment of arsenic trioxide (0–6 µg/mL) did not 
significantly (p < 0.05) alter the cell cycle distribution (Figure 5). 
Figure 5. Effect of arsenic trioxide on cell cycle distribution in A549 cells. 
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The graph represents the sub-G1 (M1), G1/G0 (M2), S (M3) and G2 (M4) percentages of cell cycle 
distribution from three independent experiments performed in triplicates.  
 
4. Discussion 
 
[
3H]thymidine  incorporation  is  a  tool  used  by  many  researchers  to  evaluate  the  proliferative 
response  to  a  chemical  or  drug.  The  [
3H]thymidine  is  incorporated  in  the  DNA  to  determine  the 
percentage  of  cells  in  the  DNA  synthesis  (S)  phase  of  the  cell  cycle  [21].  In  this  study,  we 
demonstrated  that  arsenic  trioxide  inhibited  DNA  synthesis  in  a  dose-dependent  manner  in  lung 
adenocarcinoma  cell  line  (A549).  DNA  synthesis  significantly  decreased  at  the  highest  level  of 
exposure. Tchounwou et al. revealed a dose-response in human liver carcinoma cells (HepG2) and 
human leukemia cells (HL-60) in reference to arsenic toxicity [7,22]. Chow et al. reported that the 
arsenic trioxide (0.25–2 μM) exhibited inhibitory effects on the proliferation of MCF-7 cells in a dose 
and time dependent manner [23]. Lau et al. confirmed that cell proliferation occurred at a lower level 
of arsenite (2 µM) in rat LEC cell line [24]. In our study, we have shown that DNA synthesis was 
inhibited by arsenic trioxide in A549 cells. Chow et al. also demonstrated that arsenic was capable of 
reducing cell survival in MCF-7 cells via the suppression of the estrogen-induced growth stimulatory 
effects  in  MCF-7  cells  [22].  Li  et  al.  tested  the  effects  of  arsenic  trioxide  in  human  pancreatic  
(AsPC-1), colonic (HT-29), and breast (MCF-7) cancer cells [25]. Their study revealed that in all three 
cancer cell lines, arsenic trioxide inhibited proliferation in a concentration and time-dependent manner, 
as measured by [
3H-methyl]thymidine incorporation and cell counting [25]. In comparison, studies 
performed by Harnagea-Theophilis et al. revealed that DNA synthesis was not stimulated in estrogen-
responsive breast cells (MCF-7) when combined with estradiol and acetaminophen [21].  
Apoptosis is an active and gene-directed form of cell death with well characterized morphological 
and  biochemical  features,  including  activation  of  a  caspase  cascade,  DNA  fragmentation  into 
nucleosomal fragments, and cleavage of various caspase substrates [4,13,15]. Studies have shown that 
arsenic induces apoptosis in several cell lines [9-11,25-27]. In our study, we demonstrated that arsenic 
trioxide also induces apoptosis in lung carcinoma (A549) cells especially at higher levels of exposure. 
Previous studies have revealed that arsenic trioxide could induce apoptosis at both lower and higher 
levels of exposure in renal, myelocytic, and liver cancer cells [25].  
According to Hockenberry et al., the ―ladder‖ pattern or DNA fragmentation is the indication of 
apoptosis [15]. Previous work in our laboratory has shown the laddering pattern in A549 cells after 48 
h treatment of arsenic trioxide at 2 μg/mL, 4 μg/mL and 6 μg/mL [28]. Coincidentally, with inhibition 
of growth, Li et al. observed other morphological changes in the colon, breast and pancreatic cancer 
cell  lines after exposure to  arsenic trioxide. These changes included  reduced cytoplasmic volume, 
membrane blebbing, and nuclear condensation, consistent with apoptosis [26]. Zheng et al. showed 
that  arsenic  trioxide  induced  apoptosis  in  human  papilloma  viruses  (HPV16)  DNA-  immortalized 
human cervical epithelial cells in vitro and selectively inhibited early viral gene expression [28].  
Caspases  are  a  family  of  proteases  that  play  a  pivotal  role  in  the  execution  of  apoptosis  [29]. 
Caspase-3 was used as a biomarker for apoptosis in this study. We observed that caspase 3 activity 
increased significantly at 6 μg/mL (3μM) of arsenic trioxide compared to the control. Previous studies Int. J. Environ. Res. Public Health 2010, 7                 
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have  shown  that  caspase  3  plays  an  essential  role  as  an  executor  in  apoptosis  [30,31].  Han  and  
Kim et al. observed a significant increase of caspase-3 activity in juxtaglomerular cells (As4.1 JG) 
treated with 7 μM arsenic trioxide for 48 h compared to control [31]. They incubated the arsenic-
treated As4.1 JG cells with caspase 3 inhibitor. The susceptibility of arsenic trioxide in A549 cells is 
lower than that in renal cells. The differing susceptibilities might result from the origin of the cells. 
One  of  the  mechanisms  by  which  arsenic  exerted  its  effects  was  through  signal-transduction 
pathways.  Therefore,  we  studied  the  effect  of  arsenic  trioxide  on  p38  MAP  kinase  in  regards  to 
apoptosis. Lau et al. conducted research on arsenic and its effect on signal transduction and found that 
arsenic  altered  the  signal  transduction  via  MAP  kinase  [23].  In  our  study,  we  observed  an  
up–regulation p38 MAPK (ATF-2 substrate expression) at 4 µg/mL of arsenic trioxide. Namgung and 
Xia  have  reported  that  the  neurotoxicity  of  arsenite  may  cause  the  activation  of  p38  and  c-Jun  
N- terminal kinase 3 (JNK3) and mitogen-activated protein kinases (MAPKs), which are involved in 
the apoptosis process [6,32].  
In our study, we observed little to no effect of arsenic on cell cycle distribution in the sub-G1 phase 
in A549 treated at 48 h. Han and Kim reported that arsenic trioxide did not significantly alter the cell 
cycle distribution in A549 cell treated for 72 h. However, they pointed out that 50 μM arsenic trioxide 
induced a G2 arrest in these same cells [33]. In a previous study, they reported that low doses of 
arsenic trioxide (1–10 μM) in As4.1 JG cells induced S phase arrest [31]. In the same cell line, they 
revealed that 1 μM arsenic trioxide did not trigger apoptosis. However, they reported a 50% elevation 
in the percentages of sub-G1 population in As4.1 JG at 20 μM arsenic trioxide [31]. We observed that 
arsenic  trioxide  induces  a  G0/G1  phase  arrest  in  a  dose-dependent  manner.  The  G0/G1  phase 
percentages  increased by two-fold at  6 μg/mL  exposure. Liu and Hilsenbeck reported that arsenic 
trioxide-induced  apoptosis  and  p53-dependent  G1  or  G2/M  cell  cycle  arrest  in  multiple  myeloma  
cells  [34].  They stated that the multiple myeloma cells  with normal p53 were resistant to arsenic 
trioxide-induced apoptosis and were arrested in G1 phase, whereas cells lacking functional p53 were 
sensitive and were arrested in G2/M phase [33]. Li and others revealed the redistribution of the cell 
cycle in solid human tumor such as breast, colon and pancreas [24]. 
5. Conclusions 
Arsenic is a well documented human carcinogen associated with various cancers, including lung 
cancer. Trisenox is a drug for treating myeloma cancer, but little is known about its mechanism in 
treating solid tumors such as non-small cell tumor lung. We have demonstrated that arsenic trioxide 
inhibited DNA synthesis in a dose-dependent manner in A549 cells. Our findings also showed that 
arsenic  trioxide  induces  apoptosis  via  caspase-3  activation  and  influenced  the  p38  MAP  kinase 
pathway. Although, arsenic trioxide did not alter the subG1 of the cell cycle, it significantly modulated 
the G0/G1 phase. The susceptibility of arsenic trioxide on sub-G0 and G0/G1 appears to depend on the 
origin of the cell (cell type). These results will lead to a better understanding of the role played by 
arsenic trioxide-induced apoptosis in the treatment of lung cancer.  Int. J. Environ. Res. Public Health 2010, 7                 
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